N/A
Manufactured by Merck Sharp & Dohme LLC
48,249 FDA adverse event reports analyzed
Last updated: 2026-04-14
FOSAPREPITANT DIMEGLUMINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Merck Sharp & Dohme LLC. The most commonly reported adverse reactions for FOSAPREPITANT DIMEGLUMINE include NAUSEA, DYSPNOEA, PYREXIA, DIARRHOEA, VOMITING. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for FOSAPREPITANT DIMEGLUMINE.
Out of 13,275 classified reports for FOSAPREPITANT DIMEGLUMINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 48,249 FDA FAERS reports that mention FOSAPREPITANT DIMEGLUMINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include NAUSEA, DYSPNOEA, PYREXIA, DIARRHOEA, VOMITING, FATIGUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Merck Sharp & Dohme LLC in connection with FOSAPREPITANT DIMEGLUMINE. Always verify the specific product and NDC with your pharmacist.